Janus tyrosine kinase (JAK) signaling may be involved in the pathogenesis of polymyalgia rheumatica (PMR), and tofacitinib may be an effective treatment, according to a pilot study published ...

Among 14 patients in a phase II study treated with the oral Janus-associated kinase (JAK) inhibitor, mean disease activity ratings on a standard scale fell from 50.9 points at baseline to just 1.3 ...

PORTLAND, Ore.--(BUSINESS WIRE)--Sparrow Pharmaceuticals today announced that it presented new data from its ongoing Phase 2 clinical trial of its HSD-1 inhibitor, clofutriben (referred to SPI-62 ...